FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2626083612> ?p ?o ?g. }

• W2626083612 endingPage "1718" @default.
• W2626083612 startingPage "1716" @default.
• W2626083612 abstract "The peroxisome proliferator-activated receptor (PPAR) family of nuclear receptor transcription factors regulate metabolism, inflammation, and immunity.1Straus D.S. Glass C.K. Anti-inflammatory actions of PPAR ligands: new insights on cellular and molecular mechanisms.Trends Immunol. 2007; 28: 551-558Abstract Full Text Full Text PDF PubMed Scopus (442) Google Scholar Pharmacological agents that activate PPAR-γ, such as thiazolidinediones (TZD), sensitize cells to insulin and are used to treat diabetes. PPAR-γ is also expressed in the lung where it has anti-inflammatory effects,2Belvisi M.G. Hele D.J. Birrell M.A. Peroxisome proliferator-activated receptor gamma agonists as therapy for chronic airway inflammation.Eur J Pharmacol. 2006; 533: 101-109Crossref PubMed Scopus (121) Google Scholar Based on the protective effects of PPAR-γ agonists in murine asthma models,2Belvisi M.G. Hele D.J. Birrell M.A. Peroxisome proliferator-activated receptor gamma agonists as therapy for chronic airway inflammation.Eur J Pharmacol. 2006; 533: 101-109Crossref PubMed Scopus (121) Google Scholar, 3Ward J.E. Tan X. Peroxisome proliferator activated receptor ligands as regulators of airway inflammation and remodelling in chronic lung disease.PPAR Res. 2007; 2007: 14983Crossref PubMed Scopus (37) Google Scholar we performed a clinical trial of the TZD, pioglitazone, to assess whether it might be beneficial for severe asthmatic patients who are persistently symptomatic despite treatment with high doses of inhaled corticosteroids with or without oral prednisone. The objective of this randomized, double-blind, placebo-controlled, 2-period, crossover study was to assess whether the primary outcome measure of the Juniper asthma quality of life questionnaire score (AQLQ) would be significantly higher at the end of the pioglitazone treatment period as compared to placebo in patients with severe asthma. This study of pioglitazone hydrochloride in severe asthma was an investigator-initiated study that was conducted at the National Institutes of Health Clinical Research Center (Bethesda, Md) between October 2009 and June 2016. Protocol 09-H-0244 was approved by the National Heart, Lung, and Blood Institute Institutional Review Board and all participants provided informed consent. Subjects whose baseline asthma status did not change during a 4-week run-in period (eg, absence of unscheduled health care visits for asthma care and no change in maintenance asthma medications) were randomized to either pioglitazone or matching placebo (see Fig E1 in this article's Online Repository at www.jacionline.org). Pioglitazone, 30 mg daily, was administered for the initial 2 weeks of the first treatment phase, followed by 45 mg daily for an additional 14 weeks. This was followed by a 4-week washout period. Subjects were assessed for clinical stability during a second 4-week run-in period prior to crossing over to the second treatment phase to receive the other agent. Therefore, each subject received both placebo and study drug at different times during the study. Detailed methods are reported in this article's Online Repository at www.jacionline.org. Of the 59 subjects screened for the study, 34 met inclusion criteria for participation and 16 subjects underwent randomization (Fig 1). The study was terminated early due to difficulty in recruiting additional subjects to achieve a sample size of 26 completers. The demographics for the 12 subjects who were enrolled, randomized, and completed the study are shown in Table E1 in this article's Online Repository at www.jacionline.org. Subjects were predominantly white with elevated body mass index, moderately severe airflow obstruction, and poor asthma control. All subjects had a history of allergy and were receiving high doses of inhaled corticosteroids. Five subjects were also receiving an inhaled long-acting β2-agonist, 2 subjects were receiving oral prednisone, and 4 subjects were receiving an inhaled long-acting β2-agonist plus oral prednisone. Eleven subjects were receiving a leukotriene-modifying agent, while 5 subjects were receiving omalizumab. Two subjects who were randomized withdrew from the study for personal reasons, while study drug administration was discontinued in 2 subjects due to adverse events of pedal edema and presumptive angioedema. Details of adverse events are reported in this article's Online Repository at www.jacionline.org and Table E2. There was no difference regarding the prespecified primary outcome measure of the Juniper AQLQ score at the end of the pioglitazone as compared to the placebo treatment period (4.7 ± 1.3 vs 4.6 ± 1.3, P = .677) (Fig 2). Similarly, no difference in the Juniper AQLQ score was observed by period (P = .456). A similar analysis was performed using a mixed-effects method to model correlation within subjects with a random intercept, which yielded the same conclusion. There were also no differences in prespecified secondary outcome measures regarding asthma symptoms or control (Fig 2), airflow obstruction and inflammation (details are reported in the Online Repository at www.jacionline.org and Figs E2-E4), except for a significantly lower peripheral blood lymphocyte count after the pioglitazone as compared to the placebo treatment periods (2.1 ± 0.8 vs 2.6 ± 1.1 thousand/μL, P = .002). Although several clinical studies generated initial evidence suggesting that the TZD class of PPAR-γ agonist medications might be beneficial for asthma,4Rinne S.T. Feemster L.C. Collins B.F. Au D.H. Perkins M. Bryson C.L. et al.Thiazolidinediones and the risk of asthma exacerbation among patients with diabetes: a cohort study.Allergy Asthma Clin Immunol. 2014; 10: 34Crossref PubMed Scopus (23) Google Scholar, 5Sandhu M.S. Dimov V. Sandhu A.K. Walters R.W. Wichman T. Casale T. The use of the peroxisome proliferator-activated receptors γ agonist rosiglitazone to treat airway hyperreactivity.Ann Allergy Asthma Immunol. 2012; 109: 75-77Abstract Full Text Full Text PDF PubMed Scopus (8) Google Scholar results from subsequent randomized clinical trials have either showed no effect or only a modest improvement in prespecified primary end points.6Spears M. Donnelly I. Jolly L. Brannigan M. Ito K. McSharry C. et al.Bronchodilatory effect of the PPAR-gamma agonist rosiglitazone in smokers with asthma.Clin Pharmacol Ther. 2009; 86: 49-53Crossref PubMed Scopus (81) Google Scholar, 7Richards D.B. Bareille P. Lindo E.L. Quinn D. Farrow S.N. Treatment with a peroxisomal proliferator activated receptor gamma agonist has a modest effect in the allergen challenge model in asthma: a randomised controlled trial.Respir Med. 2010; 104: 668-674Abstract Full Text Full Text PDF PubMed Scopus (40) Google Scholar, 8Anderson J.R. Mortimer K. Pang L. Smith K.M. Bailey H. Hodgson D.B. et al.Evaluation of the PPAR-γ agonist pioglitazone in mild asthma: a double-blind randomized controlled trial.PLoS One. 2016; 11: e0160257Crossref PubMed Scopus (23) Google Scholar, 9Dixon A.E. Subramanian M. DeSarno M. Black K. Lane L. Holguin F. A pilot randomized controlled trial of pioglitazone for the treatment of poorly controlled asthma in obesity.Respir Res. 2015; 16: 143Crossref PubMed Scopus (31) Google Scholar Here, we assessed the role of pioglitazone in severe asthma. Our cohort of severe asthmatics was characterized by a history of allergy, obesity, moderately severe airflow obstruction, and elevated FeNO consistent with airway inflammation. We show that treatment with pioglitazone for 4 months was not different than placebo regarding the prespecified, primary outcome measure of the Juniper AQLQ score. Although our study was terminated prematurely, had we continued until we had achieved 26 completers, we still would have had little chance of obtaining a significant difference between the 2 treatment arms based on a conditional power of 0.007. There were also no differences between pioglitazone and placebo regarding prespecified secondary end points, except for a reduction in peripheral blood lymphocytes in the pioglitazone treatment arm. We cannot, however, exclude the possibility that a difference between the 2 treatment arms might have been detected if the duration of the treatment period had been longer. Two of 14 subjects experienced severe adverse reactions secondary to pioglitazone. These included significant peripheral edema in 1 subject and presumptive angioedema in another. Peripheral edema is a recognized adverse effect of pioglitazone therapy that occurs because of fluid retention. Although angioedema is not known to be an adverse effect of pioglitazone, individuals with a known hypersensitivity should not receive this medication. Other potential serious side effects related to pioglitazone, such as congestive heart failure, hypoglycemia, hepatotoxicity, urinary bladder tumors, fractures, or decreased visual acuity due to macular edema did not occur. Our results suggest that pioglitazone is not safe to use in severe asthmatic patients as 14% of subjects experienced pioglitazone-related severe adverse events that necessitated discontinuation of the study medication. Furthermore, although our sample size was small, pioglitazone did not improve the primary end point of the AQLQ score. Taken collectively with the results from other clinical trials of TZDs, the absence of a positive treatment effect, as well as the potential for significant side effects, suggest that no further clinical trials of the PPAR-γ agonist, pioglitazone, should be performed for severe asthma. We are most grateful for the participation of the research subjects in this study, as well as their primary physicians. We are also very appreciative of the staffs of the National Heart, Lung, and Blood Institute Pulmonary Function Laboratory, the National Cancer Institute Cytopathology Laboratory, Dr Oleh Hnatiuk, and Dr Rita Volochayev for their contributions to this study. Download .docx (.04 MB) Help with docx files Online Repository textFig E2View Large Image Figure ViewerDownload Hi-res image Download (PPT)Fig E3View Large Image Figure ViewerDownload Hi-res image Download (PPT)Fig E4View Large Image Figure ViewerDownload Hi-res image Download (PPT)" @default.
• W2626083612 created "2017-06-23" @default.
• W2626083612 creator A5024236466 @default.
• W2626083612 creator A5028194016 @default.
• W2626083612 creator A5030610108 @default.
• W2626083612 creator A5034227091 @default.
• W2626083612 creator A5042298641 @default.
• W2626083612 creator A5044354839 @default.
• W2626083612 creator A5052485494 @default.
• W2626083612 creator A5053686286 @default.
• W2626083612 creator A5065844098 @default.
• W2626083612 creator A5077957289 @default.
• W2626083612 date "2017-12-01" @default.
• W2626083612 modified "2023-10-16" @default.
• W2626083612 title "A randomized, placebo-controlled, double-blinded, crossover trial of pioglitazone for severe asthma" @default.
• W2626083612 cites W1989838345 @default.
• W2626083612 cites W1996634393 @default.
• W2626083612 cites W2022106874 @default.
• W2626083612 cites W2059645525 @default.
• W2626083612 cites W2143176982 @default.
• W2626083612 cites W2144602391 @default.
• W2626083612 cites W2162448559 @default.
• W2626083612 cites W2180048966 @default.
• W2626083612 cites W2509276970 @default.
• W2626083612 doi "https://doi.org/10.1016/j.jaci.2017.05.033" @default.
• W2626083612 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5723231" @default.
• W2626083612 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28625806" @default.
• W2626083612 hasPublicationYear "2017" @default.
• W2626083612 type Work @default.
• W2626083612 sameAs 2626083612 @default.
• W2626083612 citedByCount "16" @default.
• W2626083612 countsByYear W26260836122017 @default.
• W2626083612 countsByYear W26260836122019 @default.
• W2626083612 countsByYear W26260836122020 @default.
• W2626083612 countsByYear W26260836122021 @default.
• W2626083612 countsByYear W26260836122022 @default.
• W2626083612 countsByYear W26260836122023 @default.
• W2626083612 crossrefType "journal-article" @default.
• W2626083612 hasAuthorship W2626083612A5024236466 @default.
• W2626083612 hasAuthorship W2626083612A5028194016 @default.
• W2626083612 hasAuthorship W2626083612A5030610108 @default.
• W2626083612 hasAuthorship W2626083612A5034227091 @default.
• W2626083612 hasAuthorship W2626083612A5042298641 @default.
• W2626083612 hasAuthorship W2626083612A5044354839 @default.
• W2626083612 hasAuthorship W2626083612A5052485494 @default.
• W2626083612 hasAuthorship W2626083612A5053686286 @default.
• W2626083612 hasAuthorship W2626083612A5065844098 @default.
• W2626083612 hasAuthorship W2626083612A5077957289 @default.
• W2626083612 hasBestOaLocation W26260836121 @default.
• W2626083612 hasConcept C126322002 @default.
• W2626083612 hasConcept C134018914 @default.
• W2626083612 hasConcept C142724271 @default.
• W2626083612 hasConcept C168563851 @default.
• W2626083612 hasConcept C204787440 @default.
• W2626083612 hasConcept C27081682 @default.
• W2626083612 hasConcept C2776042228 @default.
• W2626083612 hasConcept C2777180221 @default.
• W2626083612 hasConcept C2778384471 @default.
• W2626083612 hasConcept C2994504663 @default.
• W2626083612 hasConcept C555293320 @default.
• W2626083612 hasConcept C71924100 @default.
• W2626083612 hasConcept C87813604 @default.
• W2626083612 hasConceptScore W2626083612C126322002 @default.
• W2626083612 hasConceptScore W2626083612C134018914 @default.
• W2626083612 hasConceptScore W2626083612C142724271 @default.
• W2626083612 hasConceptScore W2626083612C168563851 @default.
• W2626083612 hasConceptScore W2626083612C204787440 @default.
• W2626083612 hasConceptScore W2626083612C27081682 @default.
• W2626083612 hasConceptScore W2626083612C2776042228 @default.
• W2626083612 hasConceptScore W2626083612C2777180221 @default.
• W2626083612 hasConceptScore W2626083612C2778384471 @default.
• W2626083612 hasConceptScore W2626083612C2994504663 @default.
• W2626083612 hasConceptScore W2626083612C555293320 @default.
• W2626083612 hasConceptScore W2626083612C71924100 @default.
• W2626083612 hasConceptScore W2626083612C87813604 @default.
• W2626083612 hasIssue "6" @default.
• W2626083612 hasLocation W26260836121 @default.
• W2626083612 hasLocation W26260836122 @default.
• W2626083612 hasLocation W26260836123 @default.
• W2626083612 hasLocation W26260836124 @default.
• W2626083612 hasOpenAccess W2626083612 @default.
• W2626083612 hasPrimaryLocation W26260836121 @default.
• W2626083612 hasRelatedWork W2132710482 @default.
• W2626083612 hasRelatedWork W2327427894 @default.
• W2626083612 hasRelatedWork W2599742769 @default.
• W2626083612 hasRelatedWork W2626083612 @default.
• W2626083612 hasRelatedWork W2910519344 @default.
• W2626083612 hasRelatedWork W4230038729 @default.
• W2626083612 hasRelatedWork W4243676849 @default.
• W2626083612 hasRelatedWork W4245243203 @default.
• W2626083612 hasRelatedWork W4296768836 @default.
• W2626083612 hasRelatedWork W2157733656 @default.
• W2626083612 hasVolume "140" @default.
• W2626083612 isParatext "false" @default.
• W2626083612 isRetracted "false" @default.
• W2626083612 magId "2626083612" @default.
• W2626083612 workType "article" @default.